TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in pain-related functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cumulative urinary sodium loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IGFBP-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Quality of recovery - 40 items questionnaire score (QoR-40)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Immune response represented by IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune response represented by IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Perfusion index of the parietal peritoneum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Japanese Encephalitis Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Yellow Fever Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Labial EMG activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood antibiotic levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative wound pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apolipoprotein B48 Production Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Parkinson's Disease Questionnaire-39 Single Index Score (PDQ-39SI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Flight distance in the flight initiation distance (FID) task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: L/P-ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of [18F]-FBA-A20FMDV2-PET imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influence of the training on global quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the plasma concentration curve from time zero to 24 hours (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough observed plasma concentration (Cpredose) over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biofeedback response in hepatitis B carriers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brain Activation - Insula Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Brain Activation - Somatosensory Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of refractive errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of reduced stereo vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of nail pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in Postoperative Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of SBMRI for detecting breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Cardiac Death
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Myocardial Infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sore throat resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Self-Management
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Engagement in mental health care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Retention in mental health treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cmax of Cilnidipine 10 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Valsartan 160 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Cilnidipine 10 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Valsartan 160 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Eyberg Child Behavior Inventory (ECBI) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: NPD Biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of pin site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of histologically verified cancer lesions identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Balance and Gait Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative grip force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of MMP 9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent agreement with Gold Standard
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in AzBio Sentences in Noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Localization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day Point Prevalence Abstinence From Cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Healing of digital ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of participants with gestational diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intracellular content of PD polyglutamates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Relapse to Drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Hemoglobin on Day 0 Compared to Preoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Hematocrit on Day 0 Compared to Preoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Autologous Transfusion Units Over the Course of the Hospital Stay
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Concentration of Matrix Metalloproteinase 2 and 9 Enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of ability to swallow 20mls of water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum score of signs and symptoms of perioral dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: iota-carrageenan concentration in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Investigator Defined Drug-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: GERD digestive expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants Self-Identifying Suicidality by Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Patient's intention to participate in TPE
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to upper and lower GI recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: EAM Max Step-count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to decrease in the Influenza and Other ARVI Severity Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfusional needs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients needing to decrease insulin dosage due to hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with specific treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with symptomatic hypoglycemia and severe hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjective rating scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of perioperative PET/CT imaging combined with handheld gamma probe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adherence to ventilator use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Laryngeal Adaptation in Speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laryngeal Adaptation in Swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants suffering neuronal infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symptom Assessment in Dry Eye (SANDE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Corneal Fluorescein Staining (CFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear Break Up Time (TBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type-specific oral HPV DNA shedding (presence versus absence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Persistence of same type HPV DNA shedding from pre-entry/baseline visits to Week 16 and 24 visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cognitive Function Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Global Function Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Hamilton Depression Rating Scale HDRS-21
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complications related to medications
Endpoint domain: Adverse events/effects
Primary endpoint: Chromosome translocation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Circumference (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients withdrawn due to toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Symptoms Severity IBS-SSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms Severity CAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms Severity CDAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under ROC curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge base for mental health disorders
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Vasomotor Reactivity to Carbon Dioxide (CO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of change in brain regions based on neuroimaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rates of change in CSF amyloid beta and CSF tau/P tau levels based on biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of change in neuropsychological measures of memory and general cognitive performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Severity of patient discomfort at incision sites
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of procedural technical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of short-term clinical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in absolute claudication walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titer (GMT) of Toxin Neutralizing Antibody (TNA) 50% Neutralization Factor (NF50) at Day 64
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving a TNA NF50 ≥0.56 on Day 64
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: total exhaled nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: bronchial nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: small airway/alveolar nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of warfarin or nifedipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liebowitz Social Anxiety Scale - Self Report
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient reported outcomes (PRO)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Age distribution of patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial diversity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe oral mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of severe oral mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of NGS on metastatic solid tumor tissue
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of NGS result-based non-FDA-approved treatment plan
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients who have one recommended therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients who have multiple options recommended
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Efficacy of early coronary angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of early coronary angiography
Endpoint domain: Adverse events/effects
Primary endpoint: Natriuresis (level of sodium in urine sample)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of BMS-955176
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-955176
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to 72 hours post-dose [AUC(0-72)] of BMS-955176
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutralizing antibody titers to DEN4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum Pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical healing of root canal treated teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expressive Language
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAI titer levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnosis of bone metabolism disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Employees' help-seeking behaviour
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in nasal symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of DNA quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ETDRS visual acuity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in 24-hour Mean Ambulatory Systolic Blood Pressure (maSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in 11-point Pain Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Pain on First Postoperative Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative assessments of perceived impact on daily life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PELOD-2 score
Endpoint domain: Mortality/survival
Primary endpoint: Correlation coefficients between nodes of the motor network
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Histologic steatosis and fibrosis grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Area under the curve of late stage peripheral blood parasitemia over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical characteristics of juvenile dermatomyositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Gastric content volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of neonatal COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of vertically transmitted COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: early postoperative cognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Dilatations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prevalence of Covid-19 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of unplanned hospital admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of A&E attendances
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of GP consultations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: change in CO2 flow and O2 flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: REE change due to CRRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate (Confirmed Complete Response or Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Breastfeeding rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness to participate in mindfulness-based behaviour therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Compliance with mindfulness-based behavior therapy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Presence or absence of mechanical alternans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MTWA (Microvolt T-Wave Alternans)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spatiotemporal parameters of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported pain questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Extent of Exposure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptance of HIV test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Expanded Disability Status Scale (EDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuro-Behçet's Disability Score (NBDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in RAVLT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: measurable lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: standardized uptake value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in intensity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes